- MilliporeSigma introduces the Mobius ADC Reactor, a single-use system designed to streamline the production of antibody-drug conjugates (ADCs).
- The new reactor aims to reduce cleaning procedures and cross-contamination risks, supporting faster and safer manufacturing processes.
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced the launch of its Mobius ADC Reactor. This single-use reactor is tailored for the production of antibody-drug conjugates (ADCs), a class of therapeutics known for targeting and killing tumour cells with minimal impact on healthy tissues.
The Mobius ADC Reactor is designed to address the specific challenges of ADC manufacturing. It eliminates the need for labour-intensive cleaning associated with traditional stainless steel or glass reactors. This reduces turnaround times and lowers the risk of cross-contamination, offering a more efficient and safer manufacturing solution for biopharmaceutical companies.
Sebastian Arana, Head of Process Solutions at MilliporeSigma, stated, “We have been providing single-use solutions for flexible biopharmaceutical manufacturing for more than 15 years. Drawing on this extensive experience, we are now ready to accelerate the production of antibody-drug conjugates.” He added that the new reactor will help customers deliver essential therapies to a global population.
The Mobius ADC Reactor features Ultimus Film technology, which enhances bag strength and durability. This design, combined with optimised chemical compatibility and quality standards, ensures high product quality while minimising waste.
Overview of outsourcing trends 
